Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effusions and pericardial effusion that has not previously...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2021-09-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/518081 |